Journal
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 4, Issue 1, Pages 57-69Publisher
ELSEVIER
DOI: 10.1016/j.nano.2007.11.005
Keywords
Radioactive composite nanodevice; Au-198; Cancer
Funding
- US Department of Energy [FG01-00NE22943]
- Department of Defense [DAMD17-03-1-0018]
- National Institutes of Health (NIH)- National Cancer Institute (NCI) [R01-CA-104479-01]
Ask authors/readers for more resources
We describe the simple fabrication of poly({Au-198}) radioactive gold-dendrimer composite nanodevices in distinct sizes ( diameter between 10 nm and 29 nm) for targeted radiopharmaceutical dose delivery to tumors in vivo. Irradiation of aqueous solutions of Au-197 containing poly( amidoamine) dendrimer tetrachloroaurate salts or {Au-197(0)} gold-dendrimer nanocomposites in a nuclear reactor resulted in the formation of positively charged and soluble poly{Au-198(0)} radioactive composite nanodevices (CNDs). A mouse melanoma tumor model was used to test whether the poly{198Au0} CNDs can deliver a therapeutic dose. A single intratumoral injection of poly{Au-198(0)}(d= 22nm) CNDs in phosphate-buffered saline delivering a dose of 74 mu Ci resulted after 8 days in a statistically significant 45% reduction in tumor volume, when compared with untreated groups and those injected with the cold nanodevice. No clinical toxicity was observed during the experiments. This study provides the first proof of principle that radioactive CNDs can deliver therapeutic doses to tumors. (c) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available